For the Inventor, By the Inventor

Enter assignee name

Vancouver, Canada

Zymeworks Inc.

USPTO Granted Patents = 56

CIPO Patents = 9

EPO Patents = 21

Trademarks = 6

Forward Citations = 334

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

Surjit Bhimarao Dixit (27 out of 27 patents)

Thomas Spreter Von Kreudenstein (14 out of 18 patents)

Paula Irene Lario (13 out of 15 patents)

4. Gordon Yiu Kon Ng (12 out of 15 patents)

5. Mario Sanches (12 out of 17 patents)

6. Eric Escobar-Cabrera (11 out of 14 patents)

7. James R Rich (10 out of 16 patents)

8. Igor Edmondo Paolo D'Angelo (9 out of 10 patents)

9. Stacey A L Tom-Yew (7 out of 10 patents)

10. Tom Han Hsiao Hsieh (7 out of 12 patents)

11. David Kai Yuen Poon (7 out of 7 patents)

12. Geoffrey C Winters (7 out of 14 patents)

13. Alexander Laurence Mandel (7 out of 12 patents)

14. Dunja Urosev (6 out of 11 patents)

15. Adam Louis Corper (6 out of 9 patents)

Core Competencies:

Drug Conjugates

Bispecific Antibodies

Antigen-Binding Constructs

Immunoglobulin Engineering

Heteromultimer Scaffolds

Cytotoxic Compounds

Polymer Dynamics

Protein Design

HER2 Targeting

Checkpoint Inhibitors

Fc Domain Mutations

Asymmetric Antibodies

56 patents: Sort by Forward Citations

1. 11560422 - Sulfonamide-containing linkage systems for drug conjugates (2023-01-24),

2. 11351251 - Anti-PD-L1-anti-TIM-3 bispecific antibodies (2022-06-07),

3. 11325981 - Bispecific antigen-binding constructs targeting Her2 (2022-05-10),

4. 11306156 - Modified antigen binding polypeptide constructs and uses thereof (2022-04-19),

5. 11286293 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2022-03-29),

6. 11248037 - Multivalent heteromultimer scaffold design and constructs (2022-02-15),

7. 11208497 - Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof (2021-12-28),

8. 11203640 - Checkpoint inhibitor bispecific antibodies (2021-12-21),

9. 11161915 - Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof (2021-11-02),

10. 11152081 - Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics (2021-10-19),

11. 11147886 - Drug-conjugated bi-specific antigen-binding constructs (2021-10-19),

12. 11098105 - Heteromultimers with reduced or silenced effector function (2021-08-24),

13. 11078296 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2021-08-03),

14. 11072658 - Anti-PD-1/LAG3 bispecific antibodies (2021-07-27),

15. 11031093 - Systems and methods for identifying thermodynamically relevant polymer conformations (2021-06-08),

Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Combining proprietary protein engineering technologies and deep domain expertise, Zymeworks aims to transform the treatment of cancer and other diseases. Their diverse pipeline includes candidates for multiple therapeutic areas, including immuno-oncology, oncology, and autoimmune diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

56 Patents

#11 in Vancouver

#233 in Canada

#12,351 in the World

Vancouver, Canada

Zymeworks Inc.

Forward Citations = 334

70 inventors:

Surjit Bhimarao Dixit (27 out of 27 patents)

Thomas Spreter Von Kreudenstein (14 out of 18 patents)

Paula Irene Lario (13 out of 15 patents)

4. Gordon Yiu Kon Ng (12 out of 15 patents)

5. Mario Sanches (12 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…